Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • EU approves Sanofi and...

    EU approves Sanofi and Regenerons dupilumab in eczema

    Written by Ruby Khatun Khatun Published On 2017-10-01T09:45:16+05:30  |  Updated On 1 Oct 2017 9:45 AM IST
    EU approves Sanofi and Regenerons dupilumab in eczema

    PARIS: The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said on Thursday.


    The move comes after the U.S. Food and Drug Administration (FDA) regulator had also approved the injectable antibody drug in March. The product is sold as Dupixent.


    Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching.


    A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are believed to be major drivers of the disease.


    Sanofi plans to submit an application to the FDA for a use of dupilumab in asthma by the end of the year and hinted recently at a possible use of the drug in nasal polyps.


    Analysts on average expect Dupixent to reach annual sales of 4.7 billion euros ($5.53 billion) by 2023, according to Thomson Reuters data.


    Shares of Regeneron and Sanofi slid earlier this month after late-stage trial data for dupilumab in asthma fell short of investor expectations. Analysts said the data appeared less impressive than the drug’s mid-stage data.


    Investors had also expressed disappointment with the sales take-up of Dupixent when Sanofi published its second-quarter results in July, although but Sanofi expressed confidence that the drug would sell well.




    (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)



    antibody drugApprovesatopic dermatitisdupilumabDupixenteczemaEUEuropean CommissionFDAinjectableRegeneronSanofiU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok